贝复舒在滴眼液行业中的票数：13
【贝复舒是哪个国家的品牌？】
成立于1996年，知名滴眼液品牌，专注于运用基因工程技术，生产及销售治疗体表创伤和眼部损伤的生物药品
珠海亿胜生物制药有限公司，成立于1996年业。2001年，亿胜生物集团在香港创业板上市，并于2011年成功转为主板上市，股票代码1061。公司于2010年按照新版GMP标准在珠海高新区建立新工厂，新厂占地面积13000多平方米，厂房建筑面积20000平方米，引用设备和生产线，并于2013年，顺利通过国家新版GMP认证，为公司扩大发展奠定了坚实的基础。
公司专注于运用基因工程技术，研发、生产和销售具有自主知识产权的创伤修复生物技术药品，包括眼表修复、体表创伤修复及神经损伤修复治疗药品。
主要产品有：贝复济外用溶液、贝复济冻干制剂、贝复新凝胶、贝复舒滴眼液及贝复舒眼用凝胶。
公司全资子公司珠海亿胜医药有限公司与辉瑞国际贸易（上海）有限公司（「辉瑞」）于2014年订立进口及服务协议，辉瑞授权亿胜医药为其适利达®滴眼液和适利加®滴眼液（统称「辉瑞眼科产品」）在中国内地进口分销商和市场开发商。辉瑞眼科产品均为降眼压药物。公司与辉瑞建立业务合作关系，有助我们与辉瑞共享分销渠道，与此同时提升本公司的品牌形象及在中国眼科领域的产品组合。
公司积极与国内外科研机构合作，跟踪生物科技的新发展步伐，不断研究、开发和推广创新生物治疗产品，改善人类健康，提高生命质量。
英文翻译：Founded in 1996, a well-known eye drops brand, focusing on the use of genetic engineering technology, production and sales of the treatment of body surface trauma and eye injury of biological drugs Zhuhai Yisheng biopharmaceutical Co., Ltd., established in 1996. In 2001, Yisheng bio group was listed on the gem of Hong Kong, and successfully converted to the main board in 2011, with the stock code of 1061. In 2010, the company established a new factory in Zhuhai high tech Zone in accordance with the new GMP standard. The new factory covers an area of 13000 square meters, with a building area of 20000 square meters. It quoted equipment and production lines. In 2013, the company successfully passed the new GMP certification, laying a solid foundation for the expansion and development of the company. The company focuses on the application of genetic engineering technology, research and development, production and sales of trauma repair biotechnology drugs with independent intellectual property rights, including eye surface repair, body surface trauma repair and nerve injury repair drugs. The main products are: bFGF topical solution, bFGF lyophilized preparation, Bei Fu Xin gel, Bei Fu Shu eye drops and Bei Fu Shu eye gel. Zhuhai Yisheng Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, entered into an import and service agreement with Pfizer International Trading (Shanghai) Co., Ltd. ("Pfizer") in 2014. Pfizer authorized Yisheng pharmaceutical to be the import distributor and market developer of its silida ® eye drops and siligar ® eye drops (collectively referred to as "Pfizer eye products"). Pfizer ophthalmic products are all antiocular drugs. The company's business partnership with Pfizer will help us share distribution channels with Pfizer, and at the same time enhance the company's brand image and product portfolio in the field of ophthalmology in China. The company actively cooperates with scientific research institutions at home and abroad, tracks the new development pace of biotechnology, continuously researches, develops and promotes innovative biotherapy products, improves human health and life quality.
浙公网安备 33011802001999号
